Effect of a Nootropic on the Cognitive Performance in Young Adults
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04790188 |
Recruitment Status :
Completed
First Posted : March 10, 2021
Last Update Posted : May 18, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cognitive Change | Dietary Supplement: Nootropic Dietary Supplement: Placebo | Not Applicable |
Cognitive decline is a worrisome consequence of normal or pathologic ageing, having a high personal, eco- nomic and societal burden; also, it could herald the onset of dementia which is associated with significant morbidity and mortality.
However, with a general increase in life expectancy and a corresponding increase in the prevalence of age-related cognitive impairment, there have been concerted efforts towards the development and adoption of preventive strategies that would minimize the risk of developing dementia, or reduce the rate of cognitive decline with ageing. In the last few decades, certain compounds have been found useful in the management of cognitive decline.
The term 'nootropic' has been used to define such substances with the capacity to enhance cognition. While research has led to the synthesis of several drugs with nootropic effects, attention is now being shifted to the discovery, characterization and utilization of nootropics from natural sources for the prevention and management of age-related cognitive decline.
25 young adults will be randomized into two conditions (nootropic and placebo conditions) with 48 hours of separation between conditions. 48h previous to the randomization the participants will perform a familiarization to avoid the learning effects.
Each evaluation day will conform to the following tests:
- Simple and multiple reaction time
- Inhibitory control
- Cognitive flexibility
- Working memory
- Creative intelligence
- Verbal fluidity
- Motivation
- Mood
- Positive and negative emotions
- Adverse effects
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Other |
Official Title: | Effect of a Nootropic on the Cognitive Performance in Young Adults |
Actual Study Start Date : | April 1, 2021 |
Actual Primary Completion Date : | September 25, 2021 |
Actual Study Completion Date : | May 15, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental intervention first.
Participants randomized to receive the nootropic first.
|
Dietary Supplement: Nootropic
10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA. Dietary Supplement: Placebo 10g of maltodextrin lemon flavor (HSN®). |
Placebo Comparator: Experimental intervention second.
Participants randomized to receive the placebo first
|
Dietary Supplement: Nootropic
10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA. Dietary Supplement: Placebo 10g of maltodextrin lemon flavor (HSN®). |
- Simple and multiple reaction time [ Time Frame: 1.5 hours ]Vienna Test System®
- Inhibitory control [ Time Frame: 1.5 hours ]Stroop test, E-Prime® software
- Working Memory [ Time Frame: 1.5 hours ]Tests Flankers and Task switching, EPrime ® software
- Working memory [ Time Frame: 1.5 hours ]N-Back y Spatial working memory , EPrime ® software
- Creative Intelligence [ Time Frame: 1.5 hours ]CREA test
- Verbal fluidity [ Time Frame: 1.5 hours ]Phonological and semantic verbal fluidity
- Motivation [ Time Frame: 1.5 hours ]Situational Motivation Scale (EMSI)
- Mood [ Time Frame: 1.5 hours ]EVEA scale
- Positive and negative emotions [ Time Frame: 1.5 hours ]PANAS scale
- Adverse effects [ Time Frame: 1.5 hours ]Visual analogue scales of adverse effects (gastrointestinal, nervous or psychologic)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male or female
- Ages 18-30 years
- BMI: 18-30.0 kg/m2
- Stable weight over the last 3 months (body weight changes<3kg)
- Participant must be capable and willing to provide consent, understand exclusion criteria, instructions and protocols.
- To talk and to read Spanish fluently.
Exclusion Criteria:
- History of neurological disease or mental disease.
- History of cardiovascular disease
- Diabetes or hypertension
- Pregnant, planning to become pregnant, or breastfeeding
- Have been treated previously or during the study period with neurological drugs.
- Have been treated previously or during the study period with prescription drugs: antihypertensive, lipid lowering, acid uric lowering, glucose lowering, beta blockers or any drug that under the investigator's judged could influence the results.
- Allergy/intolerance to any ingredient of the nootropic.
- High caffeine consumes (>300mg/day, or >3 coffees/day).
- Any non-controlled medical condition which could influence results or could be worsened by the participation in the study.
- Are deemed unsuitable by the investigator for any other reason, that prevent data collection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04790188
Spain | |
Jonatan Ruiz Ruiz | |
Granada, Spain, 18011 |
Responsible Party: | Jonatan Ruiz Ruiz, Associate professor, Universidad de Granada |
ClinicalTrials.gov Identifier: | NCT04790188 |
Other Study ID Numbers: |
NOCOPE project |
First Posted: | March 10, 2021 Key Record Dates |
Last Update Posted: | May 18, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Nootropic Agents |